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Abstract
Patients given allogeneic hematopoietic stem cell transplantation (alloHSCT) present an increased incidence of long-term
toxicities that can be attributed to the preparative regimen. We retrospectively analyzed in a population of 670 children receiving
allo-HSCT for acute leukemia the occurrence of different late effects in function of the choice made between total body
irradiation (TBI) and busulfan, as part of the preparative regimen. In univariable analysis, we found that patients treated with TBI
developed cataract in 24% of the cases compared with 4% in patients treated with BU (p= 0.0001) and that the incidence of
secondary malignant neoplasia (SMN) was higher in patients treated with TBI (18%) as compared with those prepared to the
allograft with a Bu-based regimen (0%) (p= 0.019). Conditioning regimen did not show a statistically significant correlation
with the occurrence of all the other investigated late effects. In multivariable analysis, TBI remained associated with the
occurrence of cataracts (Relative Risk: 0.33 p= 0.012) and secondary malignancies (Relative Risk 3.96 × 10e−6 p < 0.001);
however, other variables, as GvHD and disease type, were also correlated with these long-term sequels, indicating that in our
study population the preparative regimen is not the only factor influencing the incidence of these complications.
Introduction
Allogeneic hematopoietic stem cell transplantation
(alloHSCT) is a consolidated therapy for many oncological
diseases and for some non-malignant disorders affecting
the hematopoietic and the immune system [1]. Although
the results of alloHSCT have improved over years, patients
receiving this procedure during their childhood and
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becoming long-term survivors still have a shorter life
expectancy compared with both sex- and age-matched
healthy subjects and patients treated with conventional
chemotherapy, mainly because of an increased incidence
of long-term effects [2, 3]. Moreover, it has been reported
that the occurrence of long-term effects after alloHSCT,
even when it does not cause the patient’s premature death,
could still remarkably affect the quality of life of pediatric
patients [4]. Every system and every organ can be
involved; in particular, target of long-term toxicities of
alloHSCT may be the cardiovascular and respiratory sys-
tem, endocrine function (including the reproductive sys-
tem), the sensory (especially the eye and the ear), bone,
metabolic function, renal function, liver, gastrointestinal
tract and the skin [5]. The increased incidence of late
effects after alloHSCT has often been attributed, at least in
part, to a late toxicity of the preparative regimen [6],
which, in the pediatric population affected by acute leu-
kemias, is usually based on the administration of either
total body irradiation (TBI) or busulfan (Bu). In patients
under the age of 3, TBI is usually omitted because of its
very high rate of long-term toxicity in this group of
patients [7, 8]. In older children, the use of TBI or Bu, as
backbone for preparative regimen, has been compared in
both prospective and retrospective studies aimed at iden-
tifying differences in terms of efficacy and early toxicity
for both acute lymphoblastic leukemia (ALL) [9, 10] and
acute myelogenous leukemia (AML) [11–13]. These stu-
dies showed that, especially for ALL, the inclusion of TBI
in the conditioning is associated with reduction of relapse
rate [9, 10].
Data available on long-term toxicity after TBI or Bu
exposure are limited and contradictory: some authors
reported the same incidence of alterations of growth in
children receiving either TBI or Bu during the condition-
ing regimen [14, 15], while others reported an increased
risk of endocrine complications [16–18], cataract [18] and
secondary malignant neoplasia [19] in patients who had
received TBI. More recently, a retrospective analysis per-
formed on a large population of childhood cancer survi-
vors given HSCT showed a reduced incidence of late
complications after Bu. In particular, that study found a
correlation between the use of TBI and growth impair-
ment, cataract, and iron overload; a correlation between Bu
administration and the overweight and alopecia was found,
as well [20].
In consideration of the particular importance that
late effects has in the pediatric population, and of the
role that TBI has in the disease control in pediatric
hematological malignancies [21], in this multicenter
study, we investigated the impact of the use of either TBI




The study included all consecutive patients who underwent
first alloHSCT for acute leukemia between January 1st 2000
and December 31st 2012 in one of the 20 pediatric Italian
transplant Centers affiliated to AEIOP (Associazione Itali-
ana Ematologia ed Oncologia Pediatrica). To better identify
long-term effects, analyses were performed for all patients
when they reached a follow up of at least 5 years after the
allograft. Data were retrieved from the AIEOP-HSCT
Registry where every AIEOP Center reports information
on patient, donor and transplant characteristics, as well as
on outcome, according to policies approved by the local
Ethic Committee and after obtaining informed consent from
parents or legal guardians.
Inclusion criteria were: (i) age comprised between 3 and
18 years at the time of alloHSCT; (ii) diagnosis of either
ALL or AML; (iii) first myeloablative alloHSCT from
HLA-identical sibling donor or HLA-matched unrelated
donor or HLA-haploidentical donor; (iv) bone marrow,
peripheral blood stem cells and cord blood as stem cell
source (v) conditioning regimen including either intrave-
nous Bu (cumulative dose from 16 mg/kg to 12.8 mg/kg) or
oral Bu (cumulative dose 16 mg/kg) or TBI (fractionated
total dose equal to or greater than 990 cGy); and (vi)
complete morphological remission before starting the pre-
parative regimen and (vii) survival with disease remission
longer than one year after the transplantation.
Exclusion criteria were history of previous allogeneic
HSCT, diagnosis of ALL or AML in the context of Down
syndrome or of other diseases characterized by chromoso-
mal instability syndromes (i.e., AML in Fanconi Anemia),
and diagnosis of AML or ALL secondary to previous
exposure to chemotherapy or radiation. Patients underwent
clinical and hematological assessments both before and
after transplantation according to each Center’s policy.
Definitions and endpoints
The aim of this study was to evaluate the impact of TBI and
Bu (both oral and i.v. formulation) on the occurrence of
long-term sequels in a large population of pediatric patients
undergoing alloHSCT for acute leukemia.
As long-term effects, we considered occurrence of
growth impairment, alteration of gonadal function, altera-
tion of thyroid function, cataract, occurrence of secondary
malignant neoplasia and alteration of pulmonary function in
subjects surviving for more than one year after alloHSCT.
If asymptomatic, all patients were screened for the occur-
rence of long-term effects according to previously published
guidelines [22, 23] and when a toxicity was identified a
Occurrence of long-term effects after hematopoietic stem cell transplantation in children affected by. . . 1919
patient-specific diagnostic work up was established. Apart
from scheduled follow-up visits, patients and their families
were also encouraged to contact the Transplant Center at the
onset of new symptoms or worsening of already known health
problems, in order to identify toxicities in their early stage.
All patients had evaluations including height, weight,
body mass index (BMI), and Tanner staging every 6 months
and if abnormalities were noted they were referred to
endocrinologist to discuss a specific diagnostic work up,
including growth hormone dosing.
Growth impairment was defined as either failure to reach
normal height and weight for age according to the patient’s age
and genetic target or as a growth rate under the 3rd percentile.
Alteration of gonadal function in male patients was
defined as either delayed puberty, or as precocious puberty,
or as reduction of age-adjusted testosterone blood levels
associated with high levels of follicle-stimulating hormone
(FSH) and luteinizing hormone (LH), or as alteration of
number, shape or motility of spermatozoa in semen.
Alteration of gonadal function in female patients was
defined as either delayed puberty, precocious puberty, sec-
ondary amenorrhea requiring hormonal replacement ther-
apy, or reduction of age-adjusted estradiol blood levels with
high levels of FSH and LH.
Alteration of thyroid function was defined as elevation
of thyroid-stimulating hormone, associated or not with
decreased levels of free thyroxine or triiodothyronine in
repeated controls, requiring specific therapy, or as thyr-
oiditis resulting in hypothyroidism.
Patients were screened for cataract during specific
screening exams conducted by an ophthalmologist at least
every 1–3 years after the transplantation.
Secondary neoplasia screening was performed by phy-
sicians with experience in the diagnosis and the in treatment
of long-term effects after HSCT during scheduled follow-up
visits or when clinically indicated.
Patients were tested for pulmonary function by spirometry
at one-year post-transplant or once age-appropriate. In case of
inability to perform standard pulmonary function testing and
when a pulmonary toxicity was suspected an alternative
testing method was discussed with pulmonology in every
single case. Re-evaluation of pulmonary function was per
clinician discretion and it was guided by initial findings.
Transplant-related mortality (TRM) is defined as the
probability of dying without a previous relapse occurrence.
If the patient either experienced relapse or is still alive at the
end of the study time, data are censored at the relapse date
or at last follow-up date respectively.
Acute GvHD was diagnosed and staged according to
previously reported criteria [24]. For chronic GvHD con-
sidering that many data had been collected before current
staging system was adopted [25], previous staging system
was used [26].
Overall survival (OS) is defined as the probability of
survival irrespective of the disease state at any point in time.
If, at the end of the study time, the patient is still alive data
are censored at the last follow-up date.
Statistical analysis
To assess the influence of TBI and Bu administration on
occurrence of late effects, a two-tailed Fisher Test was per-
formed. In order to identify a correlation between the occur-
rence of each specific late effect and exposure to either Bu or
TBI, we first performed univariable analysis including also
the following other variables: patient gender, age at HSCT,
disease, donor type, disease status at HSCT, aGvHD, cGvHD
and the length of the follow-up. The occurrence of each late
effect was calculated as cumulative incidence (CI) to adjust
the analysis for competing risks: both leukemia relapse and
death were considered competing risks. If the patient either
experienced relapse or is still alive at the end of the study
time, data are censored at the relapse date or at last follow-up
date respectively. TRM was also calculated as a cumulative
incidence (CI) considering disease recurrence as competing
risk. The differences in terms of CI were compared using
Gray’s test. To perform multivariable analyses, we selected
variables reaching statistical significance in the univariable
analyses. Multivariable analysis was performed using logistic
regression. OS was calculated according to the Kaplan–Meier
method and the significance between the observed differences
was established by the log-rank test. In all the analyses, a
p value less than 0.05 was considered statistically significant.
All the statistical analyses were performed using NCSS
(Hintze, 2001; NCSS PASS, Number Crunched Statistical
System, Kaysville, UT, USA) and R 2.5.0 software packages.
Results
The study included 670 patients (415 males and 255
females) with a median age of 9 years (range 3–18) at time
of alloHSCT and with a median follow-up of 7 years (range
5–16) after HSCT.
Analysis used May 1st 2017 as reference date; 473
patients (70%) had received TBI, while 197 (30%) Bu.
Patient and transplant characteristics are summarized in
Table 1.
Median duration of follow up was of 7 years (range:
3–16) in the TBI group and 6 years (range: 3–16) in the
Bu group.
Overall, 38% of patients (n= 254) presented one single
late effect and 14% of patients (n= 93) presented more than
one late effect. The incidence of at least one late compli-
cation was higher in TBI-treated patients than in Bu patients
(48% vs 28%, p= 0.001). Similarly, the occurrence of more
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than two late effects was more frequent in the TBI group
(16% vs 7%, p= 0.006).
At 5 years TRM of TBI-treated and of Bu-treated
patients were 3% (95% CI: 1–5) and 3% (95% CI: 1–6),
respectively (p= 0.97). At 9 years OS of TBI-treated and of
Bu-treated patients were 92% (95% CI: 89–95) and 92%
(95% CI: 87–96), respectively (p= 0.99).
Growth alteration
Among patients given TBI, 29% (95% CI: 20–43) had
growth retardation compared with 18% (95% CI: 10–31) in
Bu-treated patients; however, this difference was not sta-
tistically significant (p= 0.45) (Table 2 and Fig. 1). Patient
age, donor type and aGvHD in our population showed a
significant correlation with the occurrence of alteration of
the growth (Table 3), while gender, disease type, disease
status at alloHSCT, cGvHD and length of the follow up did
not show any correlation with this late effect. Considering
the seriousness of growth alteration, we didn’t observe any
difference between TBI and Bu group: patients with growth
impairment needing Growth Hormone were 4 and 3% in the
two groups respectively.
Alteration of gonadal function
Patients treated with TBI had alteration of gonadal function
in 41% of the cases (95% CI: 28–61), while patients treated
with Bu in 20% (95% CI: 15–30, p= 0.14) (Table 2 and
Fig. 1). Among the other variables investigated, patient age
and gender were found to be correlated with the occurrence
of alteration of gonadal function (Table 3), while disease
type, donor type, disease status at alloHSCT, both acute and
chronic GvHD and length of the follow up did not have any
significant influence.
Alteration of thyroid function
Patients treated with TBI showed alteration of thyroid
function in 18% of the cases (95% CI: 13–26), compared
with 12% (95% CI: 7–20, p= 0.46) in patients treated with
Bu (Table 2 and Fig. 1).
Moreover, patients with a longer follow up were more
likely to develop alteration of the thyroid function; none of
the other variables investigated showed a correlation with
the occurrence of these abnormalities in our study
population.
Cataract
We found a statistically significant correlation between the
conditioning regimen and the occurrence of cataract:
patients treated with TBI developed cataract in 24% of the
cases (95% CI: 16–34), compared with 4% (95% CI: 2–10,
p= 0.0001) in patients treated with Bu (Table 2 and Fig. 1).
Also, disease type and aGvHD showed a statistically sig-
nificant impact on the occurrence of cataract (Table 3).
Patient age and gender, donor type, disease status at
alloHSCT, chronic GvHD and length of the follow up did
not correlate with the occurrence of this late effect. In
multivariable analysis, we found that patients treated with
Bu showed a reduced risk of developing cataract compared
with patients undergone to TBI (Relative Risk: 0.33 95%
CI: 0.14–0.78 p= 0.012) but also that patients who did
experience acute GvHD were more likely to develop cat-
aract as compared with patient who did not (Relative Risk
grade 2 aGvHD 3.5 95% CI: 1.62–7.75 p= 0.0015; Rela-
tive Risk grade 3 aGvHD 7.29 95% CI: 3.06–17.36 p <
Table 1 Patients and transplants characteristics.
TBI n= 473 Bu n= 197 p
Gender
Male 62% (294) 61% (121) 0.92
Female 38% (179) 39% (76)
Age
3–5 years 11% (53) 17% (33) 0.24
5–10 years 44% (208) 34% (66)
10–15 years 30% (143) 38% (74)
15–18 years 15% (69) 11% (24)
Disease
ALL 95% (450) 24% (47) <0.0001
AML 5% (23) 76% (150)
Phase
CR1 36% (170) 74% (145) <0.0001
CR2 58% (273) 25% (49)
Others 6% (30) 1% (3)
Donor
MFD 38% (179) 51% (101) 0.04
UD 50% (239) 42% (82)
PMFD 12% (55) 7% (14)
HSC source
BM 75% (353) 79% (155) 0.51
PBSC 16% (74) 14% (27)
CB 9% (46) 7% (15)
Acute GvHD
Absent 33% (155) 39% (76) 0.21
Grade 1 27% (127) 22% (44)
Grade 2 32% (151) 28% (55)
Grade 3 7% (34) 8% (16)
Grade 4 1% (6) 3% (6)
Chronic GvHD
Absent 73% (346) 72% (141) 0.25
Limited 15% (70) 19% (38)
Extensive 12% (56) 9% (18)
ALL acute lymphoblastic leukemia, AML acute myelogenous leuke-
mia, CR complete hematological remission, MFD matched family
donor, UD unrelated donor, PMFD partially matched familiar donor,
BM bone marrow, PBSC peripheral blood hematopoietic stem cells,
CB cord blood.
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0.001; Relative Risk grade 4 aGvHD 13.75 95% CI:
3.26–57.9 p < 0.001) (Table 4). We did not find a correla-
tion between disease type and development of cataract by
multivariable analysis.
Secondary malignancies
The incidence of secondary malignant neoplasia (SMN)
was higher in patients treated with TBI (18% 95% CI:
9–38) as compared with those prepared to the allograft
with a Bu-based regimen (0%) and this difference was
statistically significant (p= 0.019) (Table 2 and Fig. 1).
SNM included papillary thyroid carcinomas (n= 3),
malignant melanomas (n= 2), renal carcinoma (n= 1),
a grade IV glioma (n= 1), undifferentiated sarcoma (n=
2), neurofibroma (n= 1), hepatocellular carcinoma (n= 1)
and secondary acute myelogenous leukemia (n= 1).
In univariable analysis, disease type was correlated with
Table 2 Univariable analysis
about the role of total body
irradiation or busulfan in
determining late effects.
Variable n Events Cumulative incidence 95% CI Grey’s test
Growth impairment
TBI 425 44 29% 20–43 0.45
Bu 189 13 18% 10–31
Alteration of gonadal function
TBI 449 97 41% 28–61 0.46
Bu 191 30 20% 15–30
Alteration of thyroid function
TBI 450 54 18% 13–26 0.46
Bu 193 18 12% 8–20
Cataract
TBI 448 65 24% 16–34 <0.0001
Bu 191 6 4% 2–10
Secondary malignant neoplasm
TBI 445 25 18% 9–38 0.019
Bu 192 0 0 –
Alteration of pulmonary function
TBI 444 25 6% 4–9 0.3
Bu 190 14 8% 4–13
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Fig. 1 Cumulative Incidence of long-term effects. Cumulative
incidence of (a) growth alteration, (b) alteration of the gonadal func-
tion (c) alteration of the thyroid function (d) cataract (e) secondary
malignant neoplasia and (f) alteration of the pulmonary function
according to the conditioning regimen. TBI total body irradiation BU
busulfan iv or oral, 95% CI interval of confidence at 95%, n events.
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Table 3 Univariable analysis about the role of sex, age, disease type, donor type, disease status at the transplant, aGvHD, cGvHD and follow up
length in determining late effects: variables reaching the statistical significance.
Variable n Events Cumulative
incidence
95% CI Grey test
Growth impairment Age
3–5 years 86 12 30% 18–52 0.001
5–10 years 269 35 65% 50–76
10–15 years 204 12 19% 8–45
15–18 years 90 0 0 –
Donor
MFD 269 27 17% 9–31 0.012
MUD 306 41 33% 23–47
PMFD 67 3 12% 4–33
aGvHD
Absent 201 17 24% 13–44 0.002
Grade 1 161 16 28% 15–51
Grade 2 197 17 20% 12–32
Grade 3 50 4 22% 9–57
Grade 4 12 3 42% 16–100
Gonadal alteration Sex
Male 400 39 20% 10–39 <0.001
Female 248 33 52% 41–62
Age
3–5 years 86 12 18% 8–41 <0.001
5–10 years 269 35 32% 23–43
10–15 years 214 20 30% 24–38
15–18 years 92 5 32% 24–44
Thyroid function Follow-up length
<7 years 342 21 6% 4–10 0.01
>7 years 291 51 18% 14–24
Cataract Disease
ALL 471 64 22% 15–33 <0.001
AML 170 7 5% 2–11
aGvHD
Absent 223 9 5% 2–10 <0.001
Grade 1 166 15 20% 9–45
Grade 2 201 30 22% 16–32
Grade 3 50 14 37% 24–58
Grade 4 12 3 25% 9–67
SMN Disease
ALL 467 12 17% 7–35 0.02




Absent 400 13 4% 2–7 0.0011
Limited 104 9 9% 5–16
Extensive 72 13 19% 11–31
MFD matched family donor, UD unrelated donor, PMFD partially matched familiar donor, ALL acute lymphoblastic leukemia, AML acute
myelogenous leukemia.
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SMN incidence, as well; indeed, patients affected by ALL
developed SMN in 17% of cases (95% CI: 7–35), while no
case of SNM was observed in patients affected by AML
(p= 0.02) (Table 3).
Univariable analysis did not show a statistically sig-
nificant correlation between patient’s age and sex, donor
type, disease status at alloHSCT, aGvHD, cGvHD and
length of the follow up and the occurrence of SMN in our
study population. In multivariable analysis, we observed
that both the conditioning regimen and disease type were
related to the occurrence of SMN: patients affected by
ALL developed more frequently SNM compared with
patients affected by AML (Relative Risk 2.13 × 10e−6
95% CI: 1 × 10e−6–4.45 × 10e−6 p < 0.001) and patients
treated with TBI more frequently developed SNM com-
pared with patients given Bu during the preparation to
the allograft (Relative Risk 3.96 × 10e−6 95% CI: 1.68 ×
10e−6–9.34 × 10e−6 p < 0.001) (Table 4) In order to
evaluate the impact of SNM on survival in our study
population, we evaluated OS in patients developing
SNM and in patients who did not: OS at 9 years was 80%
(95% CI: 55–100) and 92% (95% CI: 90–95) (p= 0.3),
respectively.
Pulmonary toxicity
Considering lung toxicity, we observed a similar inci-
dence of pulmonary late effects in patients treated
with either TBI or with Bu: 6% (95% CI: 4–9) and 8%
(95% CI: 4–13) respectively (p= 0.3) (Table 2 and
Fig. 1). Among the other variables investigated in the
univariable analysis only the occurrence of chronic GvHD
was shown to correlate with lung function impairment
in a statistically significant manner (Table 3). Patient
age and sex, disease type, donor type, disease status
aGvHD and follow-up length did not show any correlation
with the occurrence of alterations of the pulmonary
function.
Discussion
AlloHSCT is able to offer to many children affected by
several both malignant and non-malignant diseases the best
opportunities to be cured; however, the risk of developing
long-term toxicity is still a matter of concern for pediatric
hematologists and oncologists to be carefully considered in
planning the therapeutic strategy for their patients [4].
Together with monitoring strategies aimed at timely diag-
nosing the occurrence of late effects [22], one of the vari-
ables more suitable for intervention is the choice of the
preparative regimen. Since the first alloHSCTs performed in
the late Seventies, TBI emerged as the treatment modality
able to meet the requirements of the ideal conditioning
agent, because its ability to abrogate original recipient’s
hematopoiesis, to induce the state of immunosuppression
essential for a stable donor’s hematopoietic stem cells
engraftment and to kill residual neoplastic cells [27].
However, TBI has since been reported as one of the main
causes of long-term toxicity [28].
The most used alternative to TBI, as backbone for the
preparative regimen in pediatric patients, is represented by
Bu. Studies comparing TBI with chemo-only preparative
regimen based on Bu and specifically focusing on the
occurrence of late effects in the pediatric population are
few, usually based on small series of data and sometimes
their results are contradictory. Wingard et al. reported the
same rate of growth impairment in 47 pediatric patients
affected by different diseases and treated with either TBI or
Bu as part of preparative regimen [14]. Bernard et al. in
2009 described a series of 58 children undergoing
alloHSCT and receiving either fractioned TBI or Bu and
they concluded that preparations including Bu, even if less
toxic than those based on the use of TBI, also have adverse
effects on growth [15]. The largest study, investigating the
differences in terms of incidence of late effects between
patients treated with either TBI or Bu, was published more
recently by Bernard et al. These authors concluded that late-
Table 4 Multivariable analysis.
Variable Relative risk 95% CI p value
Cataract Conditioninga 0.33 0.14–0.78 0.001
Grade II aGVHDb 3.5 1.62–7.75 0.0015
Grade III aGVHDb 7.29 3.06–17.36 <0.001
Grade IV aGvHDb 13.75 3.26–57.9 <0.001
SMN Conditioninga 3.96 × 10–6 1.68 × 10–6–9.34 × 10–6 <0.001
Diseasec 2.13 × 10−6 1 × 10–6–9.34 × 10–6 <0.001
SNM secondary malignant neoplasia.
aCompared with total body irradiation as reference.
bCompared with no GvHD-Grade I aGvHD.
cCompared with acute lymphoblastic leukemia.
1924 F. Saglio et al.
effects induced by TBI are more frequent and that they
differ from the ones observed after exposure to Bu: TBI was
correlated with an increased risk of growth impairment,
cataract and iron overload, while Bu administration was
associated with overweight and alopecia [20].
To increase the knowledge about the role of TBI and Bu
in determining long-term effects, in this study, we retro-
spectively evaluated the incidence of growth impairment,
alteration of gonadal function, alteration of thyroid function,
cataract, SMN and alteration of pulmonary function in a
large population of pediatric patients given alloHSCT for
acute leukemia in the years 2000–2012. Comparing the
general occurrence of long-term toxicities in patients
exposed to either TBI or Bu, we observed that patients
exposed to TBI are more likely to develop both a single or
two or more late effects, as previously reported [20].
However, by analyzing the incidence of each single late
effect, for most of them (alteration of growth, alteration of
gonadal function, alteration of thyroid function and altera-
tion of pulmonary function), it was not possible to
demonstrate a statistically significant correlation with the
preparative regimen, even if a trend toward a higher rate of
toxicity with TBI was noticed. In the case of cataract, in
univariable analysis, we observed a statistically significant
correlation with the use of TBI, but also with occurrence of
aGvHD and disease type. When we performed a multi-
variable analysis including these variables, even if it was
still possible to demonstrate an increased risk of developing
cataract after exposure to TBI, also the occurrence of
aGvHD still remained significant, highlighting that the
preparative regimen is not the only factor that can predis-
pose to develop this complication. We confirmed that
exposure to TBI increases the risk of developing SNM as
previously reported [19] and in our study also disease type
showed a correlation with the occurrence of this late effect:
patients affected by ALL showed an increased risk as
compared with patients with AML. One explanation of this
latter finding could be that the majority of patients affected
by ALL received alloHSCT after two previous lines of
chemotherapy while most of the patients affected by AML
were transplanted in first complete remission. Another
explanation of increased risk to develop SMN for ALL
patients could be that some of them were enrolled in first-
and second-line protocols including cranio-spinal radiation
therapy to prevent or treat Central Nervous System leuke-
mia involvement before undergoing alloHSCT.
However, data about secondary malignancies should be
considered with a peculiar attention because, for this late
effect, median duration of the follow up of this study
(7 years) may preclude the detection of some forms char-
acterized by long latencies.
Our findings, differing from those of a previous report
[20], may be interpreted in view of the fact that we chose a
statistical model based on cumulative incidence to adjust
the analysis for competing risks in order to have a more
precise estimate of the incidence of late-effects, censoring
patients not at risk of presenting this complication, either
because they experienced disease relapse or because they
died for transplant-related complications. Moreover, our
data confirming a correlation between exposure to TBI and
the occurrence of SMN after alloHSCT underline the need
to identify patients at high risk of developing this com-
plication and to carefully evaluate for them the potential
benefits and risks related to the use of TBI-based pre-
parative regimens.
In our series of patients, we did not observe a sig-
nificative impact of conditioning regimen on late TRM (at 5
years 3% in both TBI and Bu group) and OS (at 9 years
92% in both TBI and Bu group) even if we observed a trend
to a reduced survival for patients developing SNM (80% vs
92% p= 0.3) that were all reported in TBI group.
Two intrinsic limitations of our study are represented by
its retrospective design and by the fact that our study
populations (i.e., children given either TBI or Bu) have
some base-line differences including disease type, disease
status at transplantation and type of donor. These differ-
ences are in large part attributable to the inclusion in the
study of patients affected by both ALL and AML, who have
different indications to alloHSCT and usually are treated
with different preparative regimens [29, 30] that usually are
based on TBI for ALL and Bu for AML; the use of mul-
tivariable analyses, however, was intended to compensate
for these differences. The retrospective design of the study
unfortunately precluded us to collect some information that
could have been of potential interest, as the assessments of
the Quality of the Life of patients.
In conclusion, our data underline that the choice of a
TBI-based preparative regimen is not the only factor able to
influence the incidence of long-term effects after alloHSCT,
that the type of late effects differs according to the pre-
parative regimen administered and that specific monitoring
strategies are needed. Along this direction, some groups
have started to investigate if strategies based on the
screening for a genetically determined susceptibility to
development of long-term effects are feasible, but results
are still preliminary [31]. Besides these further evolutions in
the management of long-term toxicities after HSCT,
nowadays it is desirable that future and ongoing prospective
clinical trials, apart from evaluating the efficacy and early
toxicity of preparative regimens, also consider their impact
on the occurrence of late effects.
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